Skip to Navigation Skip to Search Skip to Content
Search All Centers

Progress in CAR-T Cell Therapy for Myeloma: What Does the Future Hold?

Read Transcript Download/Print Transcript

Published on January 8, 2019

At a recent town meeting  in Atlanta, an audience member asks, “will CAR-T cell therapy be available to multiple myeloma patients in the near future and, if so, who is a good candidate?” Myeloma expert Dr. Rafael Fonseca, from the Mayo Clinic in Arizona, responds by explaining where research is today for the innovative immunotherapy, the goals of clinical trial studies, and CAR-T cell therapy’s potential as a curative strategy for myeloma patients. Watch now to find out more.

This town meeting is sponsored by Amgen, Janssen Pharmaceuticals and Adaptive Biotechnologies. It is produced by Patient Power in partnership with Winship Cancer Institute of Emory University.

Featuring

Partners

Winship Cancer Institute

You might also like

Transcript | Progress in CAR-T Cell Therapy for Myeloma: What Does the Future Hold?

Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, contributors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That's how you’ll get care that's most appropriate for you.

Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, contributors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That’s how you’ll get care that’s most appropriate for you.

Jack Aiello:

I desperately think they are needed.  I hope that as we get them and as we start using them we'll get better about understanding the toxicities and how to manage them and when to use them.  In theory, they could potentially be done even in a larger population than the transplanted cell, but there might be a situation where someone is very sick with other conditions, with a heart condition or a pulmonary condition, where it may not be necessarily the safest thing. 

But I think people are going to try to push the envelope with this, because as they are being used right now it's more of a rescue strategy.  Now, stay tuned.  It may be that five years from now CAR-T cells are part of the up-front therapy, maybe even instead of the stem cell transplant.  

I think there are some patients that will be cured from this.  The reality is some patients that go through stem cell transplant right now, it's a small minority, but there are patients who go through stem cell transplant, who we see in our clinics and are 15 and 20 and 25 years later and still doing very well.  

Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, contributors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That’s how you’ll get care that’s most appropriate for you.